Development and evaluation of BioScore: A biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma

Cancer

Volumn 115, Issue 10, 2009, Pages 2092-2103

  Parker, Alexander S ^a   Leibovich, Bradley C ^a   Lohse, Christine M ^a   Sheinin, Yuri ^a,b   Kuntz, Susan M ^a,b   Eckel Passow, Jeanette E ^a   Blute, Michael L ^a   Kwon, Eugene D ^a,b,c  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Biological; Carcinoma; Kidney neoplasms; Renal cell; Survival; Tumor biomarkers

Indexed keywords

B7 ANTIGEN; KI 67 ANTIGEN; SURVIVIN;

AGED; ARTICLE; BIOSCORE; BLOOD LEVEL; CANCER CLASSIFICATION; CANCER STAGING; CLEAR CELL CARCINOMA; DEATH; EVALUATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MENTAL CONCENTRATION; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM;

AGED; ALGORITHMS; ANTIGENS, CD; BIOLOGICAL MARKERS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; KI-67 ANTIGEN; KIDNEY NEOPLASMS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NOMOGRAMS; PROGNOSIS;

EID: 65649097342     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24263     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Chow WH, Devesa SS, Warren JL, et al. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281:1628-1631. (Pubitemid 29211773)
3. Wallen EM, Pruthi RS, Joyce GF, et al. Urologic Diseases in America Project. Kidney cancer. J Urol. 2007;177:2006-2018.
4. Ljungberg B, Alamdari FI, Rasmuson T, et al. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int. 1999;84:405-411. (Pubitemid 29419406)
5. Levy DA, Slaton JW, Swanson DA, et al. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol. 1998;159:1163-1167. (Pubitemid 28172785)
6. Lam JS, Leppert JT, Figlin RA, et al. Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr Urol Rep. 2005;6:7-18.
7. Figlin R, Pierce WC, Kaboo R, et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol. 1997;158:740-745.
8. Ficarra V, Galfano A, Mancini M, et al. TNM staging system for renal-cell carcinoma: current status and future perspectives. Lancet Oncol. 2007;8:554-558.
9. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19:1649-1657. (Pubitemid 32230864)
10. Kattan MW, Reuter V, Motzer RJ, et al. A postoperative nomogram for renal cell carcinoma. J Urol. 2001;166:63-67. (Pubitemid 32565343)
11. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol. 2005;173:48-51. (Pubitemid 39627669)
12. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168:2395-2400.
13. Ficarra V, Martignoni G, Lohse C, et al. External validation of the Mayo Clinic stage, size, grade and necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional clear cell renal cell carcinoma. J Urol. 2006;175:1235-1239.
14. Kim HL, Seligson D, Liu X, et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol. 2005;173:1496-1501. (Pubitemid 40524757)
15. Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66:3381-3385.
16. Parker AS, Kosari F, Lohse CM, et al. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer. 2006;107:37-45. (Pubitemid 43939028)
17. Parker AS, Lohse CM, Leibovich BC, et al. Comparison of digital image analysis versus visual assessment to assess survivin expression as an independent predictor of survival for patients with clear cell renal cell carcinoma. Hum Pathol. 2008;39:1176-1184.
18. Tollefson MK, Thompson RH, Sheinin Y, et al. Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other. Cancer. 2007;110:783-790. (Pubitemid 47257655)
19. Therneau T, Grambsch P. Modeling Survival Data: Extending the Cox Model. 1st ed. Ann Arbor, MI: Springer-Verlag; 2000:87-92.
20. Harrell FE, Lee KL, Mark DB. Multivariate prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
21. Atkins MB, Avigan DE, Bukowski RM, et al. Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res. 2004;10(18 pt 2):6277S-6281S.
22. Lam JS, Shvarts O, Leppert JT, et al. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol. 2005;173:1853-1862.
23. Tunuguntla HS, Jorda M. Diagnostic and prognostic molecular markers in renal cell carcinoma. J Urol. 2008;179:2096-2102.
24. George S, Bukowski RM. Biomarkers in clear cell renal cell carcinoma. Exp Rev Anticancer Ther. 2007;7:1737-1747.
25. Ljungberg B. Prognostic markers in renal cell carcinoma. Curr Opin Urol. 2007;17:303-308.